1.28
-0.10 (-6.93%)
| Penutupan Terdahulu | 1.37 |
| Jumlah Dagangan | 1,972,744 |
| Harga / Jualan (P/S) | 13.41 |
| Harga / Buku (P/B) | 1.57 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -1,823.76% |
| EPS Cair (TTM) | -1.62 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -3.10% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 12.07% |
| Nisbah Semasa (MRQ) | 7.63 |
| Aliran Tunai Operasi (OCF TTM) | -137.72 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -82.51 M |
| Pulangan Atas Aset (ROA TTM) | -29.21% |
| Pulangan Atas Ekuiti (ROE TTM) | -52.76% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Caribou Biosciences, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | -0.67 |
|
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 9.83% |
| % Dimiliki oleh Institusi | 53.66% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |